Merck & Co. Inc. (NYSE:MRK) said FDA granted accelerated approval to Keytruda pembrolizumab to treat primary mediastinal large B cell lymphoma in patients who have relapsed after two or more prior lines of therapy. The pharma said Keytruda is the first PD-1 inhibitor approved to treat PMBCL.
On Tuesday, Merck said Keytruda became the first PD-1 inhibitor approved to treat advanced cervical cancer.